Literature DB >> 33716928

Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review.

Martin Vališ1, Blanka Klímová1, Michal Novotný1, Roman Herzig1.   

Abstract

The aim of this mini-review is to discuss the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardioembolic ischemic stroke and transient ischemic attacks (TIA). The methodology is based on a literature review of available peer-reviewed English studies listed in PubMed. The findings reveal that aspirin remains a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA. Nevertheless, currently, there are also other agents, i.e., ticagrelor, clopidogrel, and cilostazol, that can be applied. In addition, the results indicate that time is significant not only in severe stroke but also in non-severe stroke and TIA, which suggests that antiplatelet therapy should be applied within 24 h after the first symptoms because early treatment can lead to an improvement in neurological outcomes and reduce the chance of an early subsequent stroke.
Copyright © 2021 Vališ, Klímová, Novotný and Herzig.

Entities:  

Keywords:  antiplatelet therapy; aspirin; cilostazol; clopidogrel; dipyridamole; ischemic stroke; ticagrelor; transient ischemic attack

Year:  2021        PMID: 33716928      PMCID: PMC7947293          DOI: 10.3389/fneur.2021.626106

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  28 in total

Review 1.  Diagnosis and management of acute ischemic stroke: speed is critical.

Authors:  Tapuwa D Musuka; Stephen B Wilton; Mouhieddin Traboulsi; Michael D Hill
Journal:  CMAJ       Date:  2015-08-04       Impact factor: 8.262

Review 2.  Oral antiplatelet therapy in stroke prevention. Minireview.

Authors:  Michal Kral; Roman Herzig; Daniel Sanak; David Skoloudik; Ivanka Vlachova; Andrea Bartkova; Petr Hlustik; Michal Kovacik; Petr Kanovsky
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2010-09       Impact factor: 1.245

3.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Authors:  Yongjun Wang; Yilong Wang; Xingquan Zhao; Liping Liu; David Wang; Chunxue Wang; Chen Wang; Hao Li; Xia Meng; Liying Cui; Jianping Jia; Qiang Dong; Anding Xu; Jinsheng Zeng; Yansheng Li; Zhimin Wang; Haiqin Xia; S Claiborne Johnston
Journal:  N Engl J Med       Date:  2013-06-26       Impact factor: 91.245

Review 4.  Dual antiplatelet therapy for secondary stroke prevention: Use of clopidogrel and acetylsalicylic acid after noncardioembolic ischemic stroke.

Authors:  Karolina Koziol; Vanessa Van der Merwe; Erin Yakiwchuk; Lynette Kosar
Journal:  Can Fam Physician       Date:  2016-08       Impact factor: 3.275

5.  Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack.

Authors:  Hammad Rahman; Safi U Khan; Fahad Nasir; Tehseen Hammad; Michael A Meyer; Edo Kaluski
Journal:  Stroke       Date:  2019-04       Impact factor: 7.914

Review 6.  Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.

Authors:  Jorge Duconge; Dagmar F Hernandez-Suarez
Journal:  Curr Clin Pharmacol       Date:  2017

7.  The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.

Authors:  Jan Steffel; John W Eikelboom; Sonia S Anand; Olga Shestakovska; Salim Yusuf; Keith A A Fox
Journal:  Circulation       Date:  2020-05-21       Impact factor: 29.690

8.  Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke.

Authors:  Fan He; Cheng Xia; Jing-Hua Zhang; Xiao-Qiu Li; Zhong-He Zhou; Feng-Peng Li; Wei Li; Yan Lv; Hui-Sheng Chen
Journal:  J Clin Neurosci       Date:  2014-09-10       Impact factor: 1.961

9.  Burden of Stroke in Europe: Thirty-Year Projections of Incidence, Prevalence, Deaths, and Disability-Adjusted Life Years.

Authors:  Hatem A Wafa; Charles D A Wolfe; Eva Emmett; Gregory A Roth; Catherine O Johnson; Yanzhong Wang
Journal:  Stroke       Date:  2020-07-10       Impact factor: 7.914

10.  Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial.

Authors:  Pierre Amarenco; Hans Denison; Scott R Evans; Anders Himmelmann; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Yongjun Wang; S Claiborne Johnston
Journal:  JAMA Neurol       Date:  2020-11-07       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.